Replies to post #28805 on Sigma Labs Inc (SASI)

[auntie wynn]

who cares load from here, could go down to 04.8 but who cares load.

[monkeybuilt]

Be fair. Gary has been getting a lot of shit lately. Save it for a long term. He doesn't give trading advice. He has introduced some great companies and looks at a longer picture.

My approach is to use his tips to BEGIN DD. From there form your own opinion.

The 3D sector has been slammed in 2014. Many analysts have lost credibility over it in the short term. In the long term...they will have the last laugh as will I.

[BiotechValues]

My take on SGLB..since it's a topic here apparently

I first wrote about SGLB when it was just under .03/share and I still have those shares.

However, my enthusiasm for Sigma Labs has been tempered greatly by delays in commercialization and the overhang of the $100 million in funding they're looking for. When I wrote my first article on SGLB I pointed out that the share structure was an issue. Since then it's had further dilution and additional dilution is likely pending.

3D printing stocks went crazy in the summer/fall of 2013, and I was writing about them prior to the parabolic moves they made. They are now being valued based on earnings/revenue and not hype which is exactly as it should be.

SGLB has a market cap of $40 million and revenue of $322,000 for the last 9 months. Is that a justifiable market cap? Only the market can decide that over time... not me, not any single individual.

For the sake of comparison, look at this 8-K from BIAD filed in December (with no press release)
https://www.sec.gov/Archives/edgar/data/1370030/000118518514003407/bioamd8k121914.htm

A biotech stock that appears to be on the verge of receiving $1M in revenue, with no debt, that hasn't diluted for the last 3 years, with a market cap of $5 million.

There are others out there like this of course. But I think it drives home the fact that if 3D printing stocks are to be valued based on fundamentals, the moves we saw in 2013 are a thing of the past.

I have trimmed back both my position and expectations of SGLB based on delays in commercialization, slower than anticipated revenue growth, and probable future dilution. This is true for almost all stocks in the 3D printing space, not just SGLB.

JMO